Microencapsulated sodium butyrate (MATRIS® technology)
IPS s.r.l., Italy
Microencapsulated sodium butyrate MATRIS®
Other brands
Microencapsulated sodium butyrate in MATRIS® technology – controlled release in the intestine
Dual protection: DRcaps® capsules + MATRIS® microcapsules
Free from preservatives, carriers and unnecessary additives
Pharmaceutical-grade production (cGMP)
No unpleasant smell or aftertaste
Fully vegan formula
Research shows that sodium butyrate is the primary energy source for intestinal epithelial cells (colonocytes). It supports their regeneration and strengthens the intestinal barrier – limiting the passage of unwanted substances into the bloodstream(1,2).
Sodium butyrate is produced naturally in the colon through the fermentation of fiber by gut bacteria. Research shows that its intake may help restore microbiota balance in states of dysbiosis(3). Studies also indicate it may curb excessive activity of pro-inflammatory bacteria and support the growth of beneficial species(4).
Sodium butyrate may support dietary management of diarrhea of various origins – infectious, post-antibiotic, or related to food intolerances. Studies show it may help shorten the duration of diarrhea and reduce intestinal inflammation(5,6). In cases of irritable bowel syndrome, sodium butyrate may ease symptoms such as abdominal pain, bloating, and irregular bowel movements(1).
Preclinical and clinical studies have shown that sodium butyrate may modulate the inflammatory response – influencing cytokine expression and the activity of the intestinal immune system(7).
Research suggests that sodium butyrate may positively influence digestive comfort – helping reduce bloating, heaviness, and abdominal pain. These benefits may stem from its anti-inflammatory effects, support for the microbiota, and its role in regenerating the intestinal epithelium(1,8).
Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008 Jan 15;27(2):104-19. doi: 10.1111/j.1365-2036.2007.03562.x. Epub 2007 Oct 25. PMID: 17973645.
Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011 Mar 28;17(12):1519-28. doi: 10.3748/wjg.v17.i12.1519. PMID: 21472114; PMCID: PMC3070119.
Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilán CG, Salazar N. Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health. Front Microbiol. 2016 Feb 17;7:185. doi: 10.3389/fmicb.2016.00185. PMID: 26925050; PMCID: PMC4756104.
Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017 Jan;19(1):29-41. doi: 10.1111/1462-2920.13589. Epub 2016 Dec 8. PMID: 27928878.
Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S, Corazza GR. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharmacol Ther. 2005 Nov 1;22(9):789-94. doi: 10.1111/j.1365-2036.2005.02639.x. PMID: 16225487.
Banasiewicz T, Krokowicz Ł, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P, Walkowiak J, Drews M. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013 Feb;15(2):204-9. doi: 10.1111/j.1463-1318.2012.03152.x. PMID: 22738315.
Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut. 2000 Sep;47(3):397-403. doi: 10.1136/gut.47.3.397. PMID: 10940278; PMCID: PMC1728045.
Fachi JL, Felipe JS, Pral LP, da Silva BK, Corrêa RO, de Andrade MCP, da Fonseca DM, Basso PJ, Câmara NOS, de Sales E Souza ÉL, Dos Santos Martins F, Guima SES, Thomas AM, Setubal JC, Magalhães YT, Forti FL, Candreva T, Rodrigues HG, de Jesus MB, Consonni SR, Farias ADS, Varga-Weisz P, Vinolo MAR. Butyrate Protects Mice from Clostridium difficile-Induced Colitis through an HIF-1-Dependent Mechanism. Cell Rep. 2019 Apr 16;27(3):750-761.e7. doi: 10.1016/j.celrep.2019.03.054. PMID: 30995474.
Twoja opinia może zostać wykorzystana w naszej reklamie. Przeczytaj więcej w naszym Regulaminie. Także w opiniach dbamy o transparentność. Weryfikujemy czy pochodzą od regularnych klientów (nie osób z nami współpracujących) oraz czy są zgodne z przepisami prawa mającymi na celu ochronę konsumentów.